Assessments for Emerging Pharmaceutics Top-Up Ranking “EPTUR” include the main four categories of clinical and market identifications to ensure the productions and APIs meet the direct essentials for adding in the list. “EPTUR” has the concentrative focus on emerging generic pharma productions based on the streamed indicators as:
- Generic Regulations Identification
- Clinical Approval Identification
- Brand Equity Strategy
- Market Share Achievements (Local & Global)
By using the strategy of comprehensive evaluation of emerging generic pharmaceuticals, stakeholders and subscribers will use the facilities of collected, normalized and sorted data resource feeds of APIs beside of keeping in touch with the latest developments of emerging pharmaceuticals regulations and market brands.
The strategies of sorting and ranking the APIs strongly depend on sustaining the production and market dissemination features. Without a defined plan of presenting APIs, EPTUR can not warrant the recording, sorting and ranking them. A self-assessment survey by API suppliers must be submitted in advance for the internal reviewing and confirming the mandatory steps forward. Once hearing the approval of self-assessment process, A selected board of external advisers and experts will evaluate the API technical and commercial assignments and the decision will be made per case after a successful external evaluation.
Technology-aimed Data Process and Analysis
The process of data analysis through EPTUR uses Artificial Intelligence and Big Data compounded solutions to strength the integration of assigned data sources. Given the priorities and importance of streaming the assigned data in EPTUR, Both types of matrix-based and chart-based analytics are supported.